NEW YORK - Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company, has announced the appointment of Mary Tagliaferri, M.D., to its Board of Directors, effective February 29, 2024.
Dr. Tagliaferri, with nearly three decades of experience in the biopharmaceutical industry and a focus on oncology therapeutic development, joins the board as the company seeks to advance its novel Self-Assembly DisAssembly Pretargeted Radioimmunotherapy (SADA PRIT) technology platform and lead clinical programs.
President and CEO of Y-mAbs, Michael Rossi, expressed enthusiasm for Dr. Tagliaferri's appointment, citing her extensive industry leadership experience and expertise in developing cancer therapies as invaluable assets to the company. Dr. Tagliaferri, currently the Chief Medical Officer and Senior Vice President at Nektar Therapeutics (NASDAQ:NKTR), has a track record of leading clinical studies in oncology and establishing strategic partnerships.
Her career in biotechnology includes roles such as Chief Medical Officer for KangLaiTe-USA and Co-Founder, President, and Board Member of Bionovo, Inc. Additionally, she serves on the board of Enzo Biochem, Inc., and was previously on the board of RayzeBio, Inc. until its acquisition by Bristol-Myers Squibb (NYSE:BMY) in 2024.
Y-mAbs is focused on developing innovative cancer treatments, including radioimmunotherapy and antibody-based therapeutics. The company's pipeline features DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with high-risk neuroblastoma relapsed or refractory in the bone or bone marrow.
The information in this article is based on a press release statement from Y-mAbs Therapeutics, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.